ReviewTheranostics2013
Molecular imaging of chemokine receptor CXCR4.
Review in Theranostics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 88 citations in OpenAlex.
- Future of radiotheranostics.BMJ oncology · 2026Review
- Potential role ofAsia Oceania journal of nuclear medicine & biology · 2026Article
- Review
- Recent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors.Mini reviews in medicinal chemistry · 2025Review
- Design of a NewCurrent radiopharmaceuticals · 2024Article
- Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.Korean journal of radiology · 2023Review
- Druggability of Targets for Diagnostic Radiopharmaceuticals.ACS pharmacology & translational science · 2023Review
- Advances in the molecular imaging of primary aldosteronism.Annals of nuclear medicine · 2023Review
- Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications.Journal of medicinal chemistry · 2023Article
- The Role of PET/CT in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αPharmaceutics · 2022Article
- The Role of [Cancers · 2022Review
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- PET Imaging Radiotracers of Chemokine Receptors.Molecules (Basel, Switzerland) · 2021Review
- At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.Journal of leukocyte biology · 2021Review
- Automated Synthesis of Fluorine-18 Labeled CXCR4 Ligand via the Conjugation with Nicotinic AcidMolecules (Basel, Switzerland) · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Development of NovelBiomolecules · 2020Article
- Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases.Science advances · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CXCR4 was found to be expressed by many different types of human cancers and its expression has been correlated with tumor aggressiveness, poor prognosis and resistance to chemotherapy. CXCR4 was also shown to contribute to metastatic seeding of organs that express its ligand CXCL12 and support the survival of these cells. These findings suggest that CXCR4 is a potentially attractive therapeutic target, and several antagonists and antibodies for this receptor were developed and are under clinical evaluation. Quantifying CXCR4 expression non-invasively might aid in prognostication as a mean for personalized therapy and post treatment monitoring. Multiple attempts were done over the recent years to develop imaging agents for CXCR4 using different technologies including PET, SPECT, fluorescent and bioluminescence, and will be reviewed in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.